Annual Whole-Body, Low-Dose CT Aids Management of Smoldering Multiple Myeloma
By Lori Solomon HealthDay Reporter
TUESDAY, April 22, 2025 -- Annual whole-body, low-dose computed tomography (WBLDCT) can improve the management of smoldering multiple myeloma (SMM), according to a study published online March 25 in the Journal of Clinical Medicine.
Ioannis Ntanasis-Stathopoulos, M.D., Ph.D., from the General Alexandra Hospital and National and Kapodistrian University of Athens in Greece, and colleagues evaluated the role of WBLDCT in the early identification of bone progression in patients with SMM. The analysis included 113 patients monitored with annual WBLDCT assessments.
The researchers found that 36.3 percent of participants progressed to symptomatic multiple myeloma. Nearly one in 10 with progression (9.7 percent) progressed solely with bone lesions.
"In conclusion, the evidence presented underscores the crucial role of early detection of disease progression among SMM patients and highlights WBLDCT as a valuable imaging modality in this setting," the authors write. "Given the strong association between radiologically detected bone lesions and progression risk, incorporating yearly WBLDCT assessments into the standard practice of SMM care can help refine patient monitoring and management."
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted April 2025
Read this next
Declining Childhood Vaccination May Increase Risk for Vaccine-Preventable Infections
WEDNESDAY, April 30, 2025 -- Declining childhood vaccination rates may increase outbreaks of eliminated vaccine-preventable infections within the United States, leading to a...
AACR: Incidence-Based Mortality Dropping for Young Women With Breast Cancer
TUESDAY, April 29, 2025 -- Incidence-based mortality (IBM) declined from 2010 to 2020 among women aged 20 to 49 years diagnosed with breast cancer, according to a study presented...
AACR: Nonsurgical Treatment Feasible for Mismatch Repair-Deficient Tumors
TUESDAY, April 29, 2025 -- A neoadjuvant programmed cell death 1 (PD-1) blockade enables nonoperative management among patients with early-stage mismatch repair-deficient (dMMR)...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.